Selected adverse events reported after COVID-19 vaccination

Details

• Corporate Authors:
  National Center for Immunization and Respiratory Diseases (U.S.). Division of Viral Diseases.
• Description:
  Updated Sept. 12, 2023
  
  COVID-19 vaccine recommendations have been updated as of September 12. The content on this page is no longer current and will be updated to align with the new recommendations
  
  At the April 19, 2023 meeting of the Advisory Committee on Immunization Practices, CDC presented data related to further analyses of a preliminary safety signal for persons ages 65 years and older who received the updated (bivalent) Pfizer-BioNTech COVID-19 vaccine in one safety monitoring system, the Vaccine Safety Datalink (VSD). Other safety monitoring systems have not observed similar findings. As time has passed and more safety data have accumulated, the initial finding has decreased, and scientists believe factors other than vaccination might have contributed to the initial finding. The current evidence does not support the existence of a safety issue. FDA and CDC will continue to evaluate data as they are available and update the public as needed.
  
  
• Content Notes:
  What You Need to Know -- Anaphylaxis after COVID-19 Vaccination -- Reports of Deaths after COVID-19 Vaccination -- Guillain-Barré Syndrome (GBS) after COVID-19 Vaccination -- Myocarditis and Pericarditis after COVID-19 Vaccination -- Thrombosis with Thrombocytopenia Syndrome (TTS) after COVID-19 Vaccination.
• Subjects:
  Cause Of Death Coronavirus Infections/mortality COVID-19 Vaccines/adverse Effects COVID-19/mortality Death Certificates Heart Diseases/mortality Mortality Pandemics Vital Statistics
• Document Type:
  Webpage
• Collection(s):
  Stephen B. Thacker CDC Library
• Main Document Checksum:
  urn:sha256:a2b308fc325d08c67b64bd4f04e38587c333faa79d66df850ab8729e60285fb0
• Download URL:
  https://stacks.cdc.gov/view/cdc/133061/cdc_133061_DS1.pdf
• File Type:
  [PDF - 462.95 KB ]